Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

GSD Ia and a Semaglutide Case Report

A 2026 case report shows why a rare glucose-storage disorder changed the semaglutide plan for one adolescent with obesity and liver lesions.

Why we wrote this. This case raises a narrow GLP-1 safety question: how a rare diagnosis can change the context for a medicine that otherwise fits obesity care.

In this article (4 sections)
  1. What the case report found
  2. Why GSD Ia changes the glucose question
  3. What the report does and does not mean for GLP-1 readers
  4. What we do not yet know

A 2026 case report describes why clinicians stopped semaglutide in a 16-year-old after genetic testing confirmed glycogen storage disease type Ia, also called GSD Ia. He had severe obesity, fatty liver changes, high liver enzymes and multiple liver lesions initially managed as metabolic dysfunction-associated steatotic liver disease. The report says he experienced hypoglycaemia while using semaglutide and later began glucose monitoring and clinician-directed cornstarch therapy[1].

This is one patient. It is not evidence that semaglutide is unsafe for the general population or for everyone with fatty liver disease. Its peptide-relevant point is narrower: a medicine commonly used for obesity may need reassessment when a person has an unrecognised disorder that makes maintaining blood glucose difficult. The paper does not provide a dosing rule, a rate of hypoglycaemia, or proof that semaglutide alone caused the episodes.

What the case report found

The patient was referred for persistently elevated alanine aminotransferase, enlarged fatty liver and severe obesity. Imaging found multiple hepatic lesions. MRI suggested hepatocellular adenomas, benign liver tumours that still need specialist evaluation. Initial biopsy showed steatosis without fibrosis and did not settle the cause of the lesions. Semaglutide was used for about eight months as part of management for the presumed fatty-liver and obesity picture[1].

Because the MRI findings remained concerning, the team referred him for genetics. Trio exome sequencing identified two variants in the G6PC gene and confirmed GSD Ia. The report also describes raised uric acid and triglycerides, more than 10 adenomas, and a borderline-low HbA1c. Those details mattered because GSD Ia can overlap with obesity-related metabolic findings rather than announcing itself with one obvious sign[1].

After diagnosis, the clinical team recommended uncooked cornstarch therapy with close glucose monitoring. They stopped semaglutide because of the reported hypoglycaemia and concern that delayed gastric emptying could affect administration and effectiveness of cornstarch. That decision belongs to the facts of this case. It is not a reason for a reader to stop a GLP-1 medicine without speaking to the prescriber managing it.

Why GSD Ia changes the glucose question

GSD Ia is an inherited disorder caused by changes affecting glucose-6-phosphatase activity. That enzyme is part of the final step that releases free glucose from glucose-6-phosphate during glycogen breakdown and gluconeogenesis. When the system fails, short periods without food can lead to severe hypoglycaemia. A 2021 review describes medically prescribed dietary treatment and glucose replacement with uncooked cornstarch as central to management, with treatment individualized by metabolic specialists[2].

That is a different setting from routine obesity care. Semaglutide is a GLP-1 receptor agonist, and its effects on appetite, food intake and gastric emptying can be relevant when a person depends on carefully timed carbohydrate treatment. The case authors state that there are no data establishing use of GLP-1 medicines in paediatric patients with GSD Ia and hepatocellular adenomas. They call the impact on serum glucose in that population unknown[1].

The broader GSD Ia review helps explain the caution without proving a drug interaction. It reports that people with the condition remain at risk of hypoglycaemia despite dietary treatment, and that regular glucose monitoring and specialist dietary planning are part of current care[2]. It does not test semaglutide, so it cannot tell us how often a GLP-1 medicine would alter that risk.

What the report does and does not mean for GLP-1 readers

The report is useful as a diagnostic reminder, not as a general contraindication. The authors focused on an adolescent male with multifocal liver adenomas, liver enlargement and metabolic features that could resemble MASLD. They argue that such adenomas should prompt consideration of inherited metabolic disease. A reader with obesity or elevated liver enzymes alone should not infer they have GSD Ia from this case[1].

Likewise, the paper cannot distinguish every contributor to the reported low-glucose episodes. It does not include a comparison group, a controlled semaglutide withdrawal and restart, or systematic glucose measurements before and after each exposure. It also concerns a minor with a rare genetic condition. The available semaglutide research overview covers a much wider evidence base, but it does not answer safety questions for this rare condition.

For someone already diagnosed with GSD Ia, this case supports bringing any obesity medicine, eating changes and symptoms that could suggest low glucose to the metabolic team and prescribing clinician. For someone without that diagnosis, recurrent symptoms, a complicated liver work-up or a medicine plan that no longer fits should be assessed by a clinician rather than managed through self-adjustment. Our GLP-1 safety guide gives broader context on questions to take to that appointment.

What we do not yet know

We do not know whether GLP-1 receptor agonists raise, lower, or leave unchanged the risk of hypoglycaemia in people with GSD Ia. We also do not know whether the concern about delayed gastric emptying and cornstarch delivery produces a clinically meaningful effect across patients. The 2026 paper identifies no paediatric GSD Ia data for GLP-1 medicines. The 2021 review predates this case and describes GSD Ia management rather than GLP-1 treatment[1][2].

The sensible conclusion is limited. This case gives clinicians a reason to check whether a rare metabolic diagnosis has changed the treatment context. It does not give readers a protocol for semaglutide, cornstarch or glucose monitoring. For the evidence behind how semaglutide works, and for country-specific approval information, see our semaglutide regulation page.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Did semaglutide cause hypoglycaemia in the reported patient?

The paper reports hypoglycaemia while the patient was using semaglutide, then describes discontinuation after GSD Ia diagnosis. One case cannot prove semaglutide alone caused the episodes or estimate how often they occur.

What is glycogen storage disease type Ia?

GSD Ia is a rare inherited metabolic disorder involving glucose-6-phosphatase. It can make maintaining blood glucose difficult, especially during fasting, and usually needs specialist dietary and metabolic care.

Does this case mean people with fatty liver should avoid GLP-1 medicines?

No. The reported patient had a rare, genetically confirmed condition and multiple liver adenomas. The case does not establish a general safety finding for people with fatty liver disease or obesity.

Should a person with GSD Ia stop a GLP-1 medicine after reading this?

No. Medication changes need the metabolic team and prescribing clinician. This report identifies an uncertainty in a rare condition, not a self-management instruction.

Sources

  1. [1]Trocchia C, Herdes R, et al. GSD Ia presenting during adolescence in a male with severe obesity. JPGN Reports. 2026. PMID 42920871.Tier 1 · primary↩
  2. [2]Derks TGJ, Rodriguez-Buritica DF, et al. Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs. Nutrients. 2021. PMID 34836082.Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars